T. Rowe Price Associates
AMPE

T. Rowe Price Associates’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

T. Rowe Price Associates’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,314
Closed -$66K – 3080
2022
Q2 		$66K Buy
1,314
+557
+74% +$41.5K ﹤0.01% 2827
2022
Q1 		$107K Buy
757
+171
+29% +$25K ﹤0.01% 2833
2021
Q4 		$100K Buy
586
+155
+36% +$57.8K ﹤0.01% 2875
2021
Q3 		$215K Buy
431
+2
+0.5% +$927 ﹤0.01% 2697
2021
Q2 		$215K Buy
429
+52
+14% +$27.9K ﹤0.01% 2703
2021
Q1 		$191K Sell
377
-150
-28% -$77.4K ﹤0.01% 2700
2020
Q4 		$252K Hold
527
– – ﹤0.01% 2489
2020
Q3 		$151K Buy
527
+150
+40% +$37.2K ﹤0.01% 2474
2020
Q2 		$72K Hold
377
– – ﹤0.01% 2445
2020
Q1 		$47K Hold
377
– – ﹤0.01% 2461
2019
Q4 		$66K Hold
377
– – ﹤0.01% 2484
2019
Q3 		$57K Hold
377
– – ﹤0.01% 2483
2019
Q2 		$44K Sell
377
-5
-1% -$792 ﹤0.01% 2520
2019
Q1 		$64K Hold
382
– – ﹤0.01% 2490
2018
Q4 		$45K Buy
382
+1
+0.3% +$153 ﹤0.01% 2525
2018
Q3 		$58K Buy
381
+74
+24% +$30.9K ﹤0.01% 2561
2018
Q2 		$203K Buy
307
+92
+43% +$68.8K ﹤0.01% 2457
2018
Q1 		$220K Buy
+215
New +$180K ﹤0.01% 2387

Other funds holding AMPE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
SA
Shilanski & Associates Anchorage, Alaska $376M AUM 19.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

T. Rowe Price Associates's AMPE Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q3 2022, closing a stake of 1,314 shares — an estimated $66K sold.

T. Rowe Price Associates first reported a position in AMPE in Q1 2018 and held it in 18 quarters. The position peaked at $252K in Q4 2020. 95 funds tracked by Wall St. Rank hold AMPE as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Ampio Pharmaceuticals Inc. position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,314 Ampio Pharmaceuticals Inc. shares in Q3 2022, an estimated $66K.
  • T. Rowe Price Associates first reported a position in Ampio Pharmaceuticals Inc. in Q1 2018 and held it in 18 quarters.
  • T. Rowe Price Associates's Ampio Pharmaceuticals Inc. position peaked at $252K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.